282 results on '"Stone, G.W."'
Search Results
2. Morphodynamics of Modern and Ancient Barrier Systems: An Updated and Expanded Synthesis
- Author
-
McBride, R.A., primary, Anderson, J.B., additional, Buynevich, I.V., additional, Byrnes, M.R., additional, Cleary, W., additional, Fenster, M.S., additional, FitzGerald, D.M., additional, Hapke, C.J., additional, Harris, M.S., additional, Hein, C.J., additional, Johnson, C.L., additional, Klein, A.H.F., additional, Liu, B., additional, de Menezes, J.T., additional, Mulhern, J.S., additional, Oliver, T.S.N., additional, Pejrup, M., additional, Riggs, S.R., additional, Roberts, H.H., additional, Rodriguez, A.B., additional, Seminack, C.T., additional, Short, A.D., additional, Stone, G.W., additional, Tamura, T., additional, Wallace, D.J., additional, and Wang, P., additional
- Published
- 2022
- Full Text
- View/download PDF
3. Evaluation of cotton-gin trash blocks fed to beef cattle
- Author
-
Hill, G.M., Rivera, J.D., Franklin, A.N., Stone, G.W., Tillman, D.R., and Mullinix, B.G., Jr.
- Published
- 2013
- Full Text
- View/download PDF
4. Optical coherence tomography in coronary atherosclerosis assessment and intervention
- Author
-
Araki, M., Park, S.J., Dauerman, H.L., Uemura, S., Kim, J.S., Mario, C. di, Johnson, T.W., Guagliumi, G., Kastrati, A., Joner, M., Holm, N.R., Alfonso, F., Wijns, W., Adriaenssens, T., Nef, H., Rioufol, G., Amabile, N., Souteyrand, G., Meneveau, N., Gerbaud, E., Opolski, M.P., Gonzalo, N., Tearney, G.J., Bouma, B., Aguirre, A.D., Mintz, G.S., Stone, G.W., Bourantas, C.V., Raber, L., Gili, S., Mizuno, K., Kimura, S., Shinke, T., Hong, M.K., Jang, Y., Cho, J.M., Yan, B.P., Porto, I., Niccoli, G., Montone, R.A., Thondapu, V., Papafaklis, M.I., Michalis, L.K., Reynolds, H., Saw, J., Libby, P., Weisz, G., Iannaccone, M., Gori, T., Toutouzas, K., Yonetsu, T., Minami, Y., Takano, M., Raffel, O.C., Kurihara, O., Soeda, T., Sugiyama, T., Kim, H.O., Lee, T., Higuma, T., Nakajima, A., Yamamoto, E., Bryniarski, K.L., Vito, L. di, Vergallo, R., Fracassi, F., Russo, M., Seegers, L.M., McNulty, I., Park, S., Feldman, M., Escaned, J., Prati, F., Arbustini, E., Pinto, F.J., Waksman, R., Garcia-Garcia, H.M., Maehara, A., Ali, Z., Finn, A.V., Virmani, R., Kini, A.S., Daemen, J., Kume, T., Hibi, K., Tanaka, A., Akasaka, T., Kubo, T., Yasuda, S., Croce, K., Granada, J.F., Lerman, A., Prasad, A., Regar, E., Saito, Y., Sankardas, M.A., Subban, V., Weissman, N.J., Chen, Y.D., Yu, B., Nicholls, S.J., Barlis, P., West, N.E.J., Arbab-Zadeh, A., Ye, J.C., Dijkstra, J., Lee, H., Narula, J., Crea, F., Nakamura, S., Kakuta, T., Fujimoto, J., Fuster, V., and Jang, I.K.
- Abstract
Optical coherence tomography (OCT) has been widely adopted in research on coronary atherosclerosis and adopted clinically to optimize percutaneous coronary intervention. In this Review, Jang and colleagues summarize this rapidly progressing field, with the aim of standardizing the use of OCT in coronary atherosclerosis.Since optical coherence tomography (OCT) was first performed in humans two decades ago, this imaging modality has been widely adopted in research on coronary atherosclerosis and adopted clinically for the optimization of percutaneous coronary intervention. In the past 10 years, substantial advances have been made in the understanding of in vivo vascular biology using OCT. Identification by OCT of culprit plaque pathology could potentially lead to a major shift in the management of patients with acute coronary syndromes. Detection by OCT of healed coronary plaque has been important in our understanding of the mechanisms involved in plaque destabilization and healing with the rapid progression of atherosclerosis. Accurate detection by OCT of sequelae from percutaneous coronary interventions that might be missed by angiography could improve clinical outcomes. In addition, OCT has become an essential diagnostic modality for myocardial infarction with non-obstructive coronary arteries. Insight into neoatherosclerosis from OCT could improve our understanding of the mechanisms of very late stent thrombosis. The appropriate use of OCT depends on accurate interpretation and understanding of the clinical significance of OCT findings. In this Review, we summarize the state of the art in cardiac OCT and facilitate the uniform use of this modality in coronary atherosclerosis. Contributions have been made by clinicians and investigators worldwide with extensive experience in OCT, with the aim that this document will serve as a standard reference for future research and clinical application.
- Published
- 2022
5. On the importance of high frequency tail in third generation wave models
- Author
-
Siadatmousavi, S. Mostafa, Jose, F., and Stone, G.W.
- Published
- 2012
- Full Text
- View/download PDF
6. Clinical Trial Design Principles and Outcomes Definitions for Device-Based Therapies for Hypertension: A Consensus Document From the Hypertension Academic Research Consortium
- Author
-
Kandzari, D.E. Mahfoud, F. Weber, M.A. Townsend, R. Parati, G. Fisher, N.D.L. Lobo, M.D. Bloch, M. Böhm, M. Sharp, A.S.P. Schmieder, R.E. Azizi, M. Schlaich, M.P. Papademetriou, V. Kirtane, A.J. Daemen, J. Pathak, A. Ukena, C. Lurz, P. Grassi, G. Myers, M. Finn, A.V. Morice, M.-C. Mehran, R. Jüni, P. Stone, G.W. Krucoff, M.W. Whelton, P.K. Tsioufis, K. Cutlip, D.E. Spitzer, E.
- Abstract
The clinical implications of hypertension in addition to a high prevalence of both uncontrolled blood pressure and medication nonadherence promote interest in developing device-based approaches to hypertension treatment. The expansion of device-based therapies and ongoing clinical trials underscores the need for consistency in trial design, conduct, and definitions of clinical study elements to permit trial comparability and data poolability. Standardizing methods of blood pressure assessment, effectiveness measures beyond blood pressure alone, and safety outcomes are paramount. The Hypertension Academic Research Consortium (HARC) document represents an integration of evolving evidence and consensus opinion among leading experts in cardiovascular medicine and hypertension research with regulatory perspectives on clinical trial design and methodology. The HARC document integrates the collective information among device-based therapies for hypertension to better address existing challenges and identify unmet needs for technologies proposed to treat the world's leading cause of death and disability. Consistent with the Academic Research Consortium charter, this document proposes pragmatic consensus clinical design principles and outcomes definitions for studies aimed at evaluating device-based hypertension therapies. © 2022 Lippincott Williams and Wilkins. All rights reserved.
- Published
- 2022
7. Optical coherence tomography in coronary atherosclerosis assessment and intervention
- Author
-
Araki, M. Park, S.-J. Dauerman, H.L. Uemura, S. Kim, J.-S. Di Mario, C. Johnson, T.W. Guagliumi, G. Kastrati, A. Joner, M. Holm, N.R. Alfonso, F. Wijns, W. Adriaenssens, T. Nef, H. Rioufol, G. Amabile, N. Souteyrand, G. Meneveau, N. Gerbaud, E. Opolski, M.P. Gonzalo, N. Tearney, G.J. Bouma, B. Aguirre, A.D. Mintz, G.S. Stone, G.W. Bourantas, C.V. Räber, L. Gili, S. Mizuno, K. Kimura, S. Shinke, T. Hong, M.-K. Jang, Y. Cho, J.M. Yan, B.P. Porto, I. Niccoli, G. Montone, R.A. Thondapu, V. Papafaklis, M.I. Michalis, L.K. Reynolds, H. Saw, J. Libby, P. Weisz, G. Iannaccone, M. Gori, T. Toutouzas, K. Yonetsu, T. Minami, Y. Takano, M. Raffel, O.C. Kurihara, O. Soeda, T. Sugiyama, T. Kim, H.O. Lee, T. Higuma, T. Nakajima, A. Yamamoto, E. Bryniarski, K.L. Di Vito, L. Vergallo, R. Fracassi, F. Russo, M. Seegers, L.M. McNulty, I. Park, S. Feldman, M. Escaned, J. Prati, F. Arbustini, E. Pinto, F.J. Waksman, R. Garcia-Garcia, H.M. Maehara, A. Ali, Z. Finn, A.V. Virmani, R. Kini, A.S. Daemen, J. Kume, T. Hibi, K. Tanaka, A. Akasaka, T. Kubo, T. Yasuda, S. Croce, K. Granada, J.F. Lerman, A. Prasad, A. Regar, E. Saito, Y. Sankardas, M.A. Subban, V. Weissman, N.J. Chen, Y. Yu, B. Nicholls, S.J. Barlis, P. West, N.E.J. Arbab-Zadeh, A. Ye, J.C. Dijkstra, J. Lee, H. Narula, J. Crea, F. Nakamura, S. Kakuta, T. Fujimoto, J. Fuster, V. Jang, I.-K.
- Subjects
genetic structures ,sense organs ,eye diseases - Abstract
Since optical coherence tomography (OCT) was first performed in humans two decades ago, this imaging modality has been widely adopted in research on coronary atherosclerosis and adopted clinically for the optimization of percutaneous coronary intervention. In the past 10 years, substantial advances have been made in the understanding of in vivo vascular biology using OCT. Identification by OCT of culprit plaque pathology could potentially lead to a major shift in the management of patients with acute coronary syndromes. Detection by OCT of healed coronary plaque has been important in our understanding of the mechanisms involved in plaque destabilization and healing with the rapid progression of atherosclerosis. Accurate detection by OCT of sequelae from percutaneous coronary interventions that might be missed by angiography could improve clinical outcomes. In addition, OCT has become an essential diagnostic modality for myocardial infarction with non-obstructive coronary arteries. Insight into neoatherosclerosis from OCT could improve our understanding of the mechanisms of very late stent thrombosis. The appropriate use of OCT depends on accurate interpretation and understanding of the clinical significance of OCT findings. In this Review, we summarize the state of the art in cardiac OCT and facilitate the uniform use of this modality in coronary atherosclerosis. Contributions have been made by clinicians and investigators worldwide with extensive experience in OCT, with the aim that this document will serve as a standard reference for future research and clinical application. © 2022, Springer Nature Limited.
- Published
- 2022
8. (240) - Methods and Preliminary Results of Implementation of Multi-Center Earlyimpella® Support in Patients with St-Segment Elevation Myocardial Infarction Complicated by Cardiogenic Shock (RECOVER IV) Trial Under Exception from Informed Consent
- Author
-
Nichol, G., Dickert, N., Adams, K., Morse, D., Morse, S., Facemire, C., Shah, K., Dasari, S., Bodnar, J., O'Neill, W., and Stone, G.W.
- Published
- 2024
- Full Text
- View/download PDF
9. Modeling hurricane waves and storm surge using integrally-coupled, scalable computations
- Author
-
Dietrich, J.C., Zijlema, M., Westerink, J.J., Holthuijsen, L.H., Dawson, C., Luettich, R.A., Jr., Jensen, R.E., Smith, J.M., Stelling, G.S., and Stone, G.W.
- Published
- 2011
- Full Text
- View/download PDF
10. Right Ventricular-Pulmonary Arterial Coupling in Patients With HF Secondary MR Analysis From the COAPT Trial
- Author
-
Brener, M.I., Grayburn, P., Lindenfeld, J., Burkhoff, D., Liu, M.D., Zhou, Z.P., Alu, M.C., Medvedofsky, D.A., Asch, F.M., Weissman, N.J., Bax, J., Abraham, W., Mack, M.J., Stone, G.W., and Hahn, R.T.
- Subjects
heart failure ,mitral regurgitation ,right ventricle ,transcatheter mitral valve repair ,ventricular-vascular coupling - Abstract
OBJECTIVES The aim of this study was to determine the prognostic impact of right ventricular (RV)-pulmonary arterial (PA) coupling in patients with heart failure (HF) with severe secondary mitral regurgitation (SMR) enrolled in the COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation) trial.BACKGROUND RV contractile function and PA pressures influence outcomes in patients with SMR, but the impact of RV-PA coupling in patients randomized to transcatheter edge-to-edge repair (TEER) vs guideline-directed medical therapy (GDMT) is unknown.METHODS RV-PA coupling was assessed by the ratio of RV free wall longitudinal strain derived from speckle-tracking echocardiography and noninvasively measured RV systolic pressure. Advanced RV-PA uncoupling was defined as RV free wall longitudinal strain/RV systolic pressure
- Published
- 2021
11. The SYNTAX score on its way out or ... towards artificial intelligence: part
- Author
-
Serruys, P.W., Chichareon, P., Modolo, R., Leaman, D.M., Reiber, J.H.C., Emanuelsson, H., Mario, C. di, Pijls, N.H.J., Morel, M.A., Valgimigli, M., Farooq, V., Klaveren, D. van, Capodanno, D., Andreini, D., Bourantas, C.V., Davies, J., Banning, A.P., Escaned, J., Piek, J.J., Echavarria-Pinto, M., Taylor, C.A., Thomsen, B., Collet, C., Pompilio, G., Bartorelli, A.L., Glocker, B., Dressler, O., Stone, G.W., and Onuma, Y.
- Published
- 2020
12. Impact of non-respect of SYNTAX score II recommendation for surgery in patients with left main coronary artery disease treated by percutaneous coronary intervention: an EXCEL substudy
- Author
-
Modolo, R. (Rodrigo), Chichareon, P. (Ply), Klaveren, D. (David) van, Dressler, O. (Ovidiu), Zhang, Y. (Yiran), Sabik, J.F. (Joseph), Onuma, Y. (Yoshinobu), Kappetein, A.P. (Arie Pieter), Stone, G.W. (Gregg), Serruys, P.W.J.C. (Patrick), Modolo, R. (Rodrigo), Chichareon, P. (Ply), Klaveren, D. (David) van, Dressler, O. (Ovidiu), Zhang, Y. (Yiran), Sabik, J.F. (Joseph), Onuma, Y. (Yoshinobu), Kappetein, A.P. (Arie Pieter), Stone, G.W. (Gregg), and Serruys, P.W.J.C. (Patrick)
- Abstract
OBJECTIVES: The SYNTAX score II (SSII) was developed from the SYNTAX trial to predict the 4-year all-cause mortality after left main or multivessel disease revascularization and to facilitate the decision-making process. The SSII provides the following treatment recommendations: (i) coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) (equipoise risk), (ii) CABG preferred (excessive risk for PCI) or (iii) PCI preferred (excessive risk for CABG). We sought to externally validate SSII and to investigate the impact of not abiding by the SSII recommendations in the randomized EXCEL trial of PCI versus CABG for left main disease. METHODS: The calibration plot of predicted versus observed 4-year mortality was constructed from individual values of SSII in EXCEL. To assess overestimation versus underestimation of predicted mortality risk, an optimal fit regression line with slope and intercept was determined. Prospective treatment recommendations based on SSII were compared with actual treatments and all-cause mortality at 4 years. RESULTS: SSII variables were available from EXCEL trial in 1807/1905 (95%) patients. For the entire cohort, discrimination was possibly helpful (C statistic = 0.670). SSII-predicted all-cause mortality at 4 years overestimated the observed mortality, particularly in the highest-risk percentiles, as confirmed by the fit regression line [intercept 2.37 (1.51-3.24), P = 0.003; slope 0.67 (0.61-0.74), P < 0.001]. When the SSII-recommended treatment was CABG, randomized EXCEL patients treated with PCI had a trend towards higher mortality compared with those treated with CABG (14.1% vs 5.3%, P = 0.07) in the as-treat population. In the intention-to-treat population, patients randomized to PCI had higher mortality compared with those randomized to CABG (15.1% vs 4.1%, P = 0.02), when SSII recommended CABG. CONCLUSIONS: In the EXCEL trial of patients with left main disease, the SSII-predicted 4-year mortality overestimated t
- Published
- 2020
- Full Text
- View/download PDF
13. Vulnerable plaques and patients: state-of-the-art
- Author
-
Tomaniak, M. (Mariusz), Katagiri, Y. (Yuki), Modolo, R. (Rodrigo), de Silva, R. (Ranil), Khamis, R.Y. (Ramzi Y.), Bourantas, C.V. (Christos), Torii, K. (Kan), Wentzel, J.J. (Jolanda), Gijsen, F.J.H. (Frank), Soest, G. (Gijs) van, Stone, P.H. (Peter), West, N.E.J. (Nick E J), Maehara, A. (Akiko), Lerman, A. (Amir), Steen, A.F.W. (Ton) van der, Lüscher, T.F., Virmani, R. (Renu), Koenig, W. (Wolfgang), Stone, G.W. (Gregg), Muller, J.E. (James), Wijns, W. (William), Serruys, P.W.J.C. (Patrick), Onuma, Y. (Yoshinobu), Tomaniak, M. (Mariusz), Katagiri, Y. (Yuki), Modolo, R. (Rodrigo), de Silva, R. (Ranil), Khamis, R.Y. (Ramzi Y.), Bourantas, C.V. (Christos), Torii, K. (Kan), Wentzel, J.J. (Jolanda), Gijsen, F.J.H. (Frank), Soest, G. (Gijs) van, Stone, P.H. (Peter), West, N.E.J. (Nick E J), Maehara, A. (Akiko), Lerman, A. (Amir), Steen, A.F.W. (Ton) van der, Lüscher, T.F., Virmani, R. (Renu), Koenig, W. (Wolfgang), Stone, G.W. (Gregg), Muller, J.E. (James), Wijns, W. (William), Serruys, P.W.J.C. (Patrick), and Onuma, Y. (Yoshinobu)
- Abstract
Despite advanced understanding of the biology of atherosclerosis, coronary heart disease remains the leading cause of death worldwide. Progress has been challenging as half of the individuals who suffer sudden cardiac death do not experience premonitory symptoms. Furthermore, it is well-recognized that also a plaque that does not cause a haemodynamically significant stenosis can trigger a sudden cardiac event, yet the majority of ruptured or eroded plaques remain clinically silent. In the past 30 years since the term 'vulnerable plaque' was introduced, there have been major advances in the understanding of plaque pathogenesis and pathophysiology, shifting from pursuing features of 'vulnerability' of a specific lesion to the more comprehensive goal of identifying patient 'cardiovascular vulnerability'. It has been also recognized that aside a thin-capped, lipid-rich plaque associated with plaque rupture, acute coronary syndromes (ACS) are also caused by plaque erosion underlying between 25% and 60% of ACS nowadays, by calcified nodule or by functional coronary alterations. While there have been advances in preventive strategies and in pharmacotherapy, with improved agents to reduce cholesterol, thrombosis, and inflammation, events continue to occur in patients receiving optimal medical treatment. Although at present the positive predictive value of imaging precursors of the culprit plaques remains too low for clinical relevance, improving coronary plaque imaging may be instrumental in guiding pharmacotherapy intensity and could facilitate optimal allocation of novel, more aggressive, and costly treatment strategies. Recent technical and diagnostic advances justify continuation of interdisciplinary research efforts to improve cardiovascular prognosis by both systemic and 'local' diagnostics and therapies. The present state-of-the-art document aims to present and critically appraise the latest evidence, developments, and future perspectives in detection, prevention, an
- Published
- 2020
- Full Text
- View/download PDF
14. Predictive value of the QFR in detecting vulnerable plaques in non-flow limiting lesions: a combined analysis of the PROSPECT and IBIS-4 study
- Author
-
Safi, H. (Hannah), Bourantas, C.V. (Christos), Ramasamy, A. (Anantharaman), Zanchin, T. (Thomas), Bär, S. (Sarah), Tufaro, V. (Vincenzo), Jin, C. (Chongying), Torii, K. (Kan), Karagiannis, A. (Alexios), Reiber, J.H.C. (Johan), Mathur, A. (Anthony), Onuma, Y. (Yoshinubo), Windecker, S.W. (Stephan), Lansky, A.J. (Alexandra), Maehara, A. (Akiko), Serruys, P.W.J.C. (Patrick), Stone, P.H. (Peter), Baumbach, A. (Andreas), Stone, G.W. (Gregg), Räber, L. (Lorenz), Safi, H. (Hannah), Bourantas, C.V. (Christos), Ramasamy, A. (Anantharaman), Zanchin, T. (Thomas), Bär, S. (Sarah), Tufaro, V. (Vincenzo), Jin, C. (Chongying), Torii, K. (Kan), Karagiannis, A. (Alexios), Reiber, J.H.C. (Johan), Mathur, A. (Anthony), Onuma, Y. (Yoshinubo), Windecker, S.W. (Stephan), Lansky, A.J. (Alexandra), Maehara, A. (Akiko), Serruys, P.W.J.C. (Patrick), Stone, P.H. (Peter), Baumbach, A. (Andreas), Stone, G.W. (Gregg), and Räber, L. (Lorenz)
- Abstract
Studies have shown that the quantitative flow ratio (QFR), recently introduced to assess lesion severity from coronary angiography, provides useful prognostic information; however the additive value of this technique over intravascular imaging in detecting lesions that are likely to cause events is yet unclear. We analysed data acquired in the PROSPECT
- Published
- 2020
- Full Text
- View/download PDF
15. Defining device success for percutaneous coronary intervention trials
- Author
-
Chang, C.C. (Chun Chin), Kogame, N. (Norihiro), Onuma, Y. (Yoshinobu), Byrne, R.A. (Robert), Capodanno, D. (Davide), Windecker, S.W. (Stephan), Morel, M.-A. (Marie-Angèle), Cutlip, D.E. (Donald), Krucoff, M. (Mitchell), Stone, G.W. (Gregg), Lansky, A.J. (Alexandra), Mehran, R. (Roxana), Spitzer, E. (Ernest), Fraser, A.G. (Andrew), Baumbach, A. (Andreas), Serruys, P.W.J.C. (Patrick), Chang, C.C. (Chun Chin), Kogame, N. (Norihiro), Onuma, Y. (Yoshinobu), Byrne, R.A. (Robert), Capodanno, D. (Davide), Windecker, S.W. (Stephan), Morel, M.-A. (Marie-Angèle), Cutlip, D.E. (Donald), Krucoff, M. (Mitchell), Stone, G.W. (Gregg), Lansky, A.J. (Alexandra), Mehran, R. (Roxana), Spitzer, E. (Ernest), Fraser, A.G. (Andrew), Baumbach, A. (Andreas), and Serruys, P.W.J.C. (Patrick)
- Abstract
Percutaneous coronary intervention with implantation of drug-eluting stents has become the most commonly performed revascularisation procedure in patients with symptomatic coronary artery disease. Continuous iterations of coronary devices incorporating changes in platform materials, geometry, strut thickness, drug release mechanisms and antiproliferative drugs have progressively reduced the rate of device-related adverse clinical events. Objective performance criteria have been proposed for clinical and angiographic outcomes of drug-eluting stents. The rate of device success has been recognised as an intraprocedural endpoint to evaluate the mechanical ability to complete a procedure with the specific device assigned by protocol in randomised comparative trials. The European Commission and the U.S. Food and Drug Administration both provide guidance documents, including the mechanistic evaluation of coronary stents, which recommend operational definitions of device success. While the majority of clinical trials investigating drugeluting stents have adopted this endpoint definition, inconsistencies in application limit the reliability of comparisons across different trials reporting device success rates. In addition, it is not uncommon that device success rates are not reported by investigators. A consistent definition of device success is essential to allow scientific comparisons of this technical performance endpoint between devices across different trials. Therefore, we performed a systematic evaluation of definitions and reporting of device success in clinical trials. We propose an extended definition as well as considerations for approaching the determination of the device success rates in future percutaneous coronary intervention trials.
- Published
- 2020
- Full Text
- View/download PDF
16. Randomized Comparison Between Everolimus-Eluting Bioresorbable Scaffold and Metallic Stent: Multimodality Imaging Through 3 Years
- Author
-
Onuma, Y. (Yoshinobu), Honda, Y. (Yasuhiro), Asano, T. (Taku), Shiomi, H. (Hiroki), Kozuma, K. (Ken), Ozaki, Y. (Yukio), Namiki, A. (Atsuo), Yasuda, S. (Satoshi), Ueno, T. (Takafumi), Ando, K. (Kenji), Furuya, J. (Jungo), Hanaoka, K.I. (Keiichi Igarashi), Tanabe, K. (Kengo), Okada, K. (Kozo), Kitahara, H. (Hideki), Ono, M. (Masafumi), Kusano, H. (Hajime), Rapoza, R. (Richard), Simonton, C. (Charles), Popma, J.J. (Jeffrey J.), Stone, G.W. (Gregg), Fitzgerald, P.J. (Peter J.), Serruys, P.W.J.C. (Patrick), Kimura, T. (Takeshi), Onuma, Y. (Yoshinobu), Honda, Y. (Yasuhiro), Asano, T. (Taku), Shiomi, H. (Hiroki), Kozuma, K. (Ken), Ozaki, Y. (Yukio), Namiki, A. (Atsuo), Yasuda, S. (Satoshi), Ueno, T. (Takafumi), Ando, K. (Kenji), Furuya, J. (Jungo), Hanaoka, K.I. (Keiichi Igarashi), Tanabe, K. (Kengo), Okada, K. (Kozo), Kitahara, H. (Hideki), Ono, M. (Masafumi), Kusano, H. (Hajime), Rapoza, R. (Richard), Simonton, C. (Charles), Popma, J.J. (Jeffrey J.), Stone, G.W. (Gregg), Fitzgerald, P.J. (Peter J.), Serruys, P.W.J.C. (Patrick), and Kimura, T. (Takeshi)
- Abstract
Objectives: The aim of this study was to investigate the vascular responses and fates of the scaffold after bioresorbable vascular scaffold (BVS) implantation using multimodality imaging. Background: Serial comprehens
- Published
- 2020
- Full Text
- View/download PDF
17. Impact of left ventricular ejection fraction on clinical outcomes after left main coronary artery revascularization
- Author
-
Thuijs, D.J.F.M. (Daan), Milojevic, M. (Milan), Stone, G.W. (Gregg), Puskas, J.D. (John), Serruys, P.W.J.C. (Patrick), Sabik, J.F. (Joseph), Dressler, O. (Ovidiu), Crowley, A. (Aaron), Head, S.J. (Stuart), Kappetein, A.P. (Arie Pieter), Thuijs, D.J.F.M. (Daan), Milojevic, M. (Milan), Stone, G.W. (Gregg), Puskas, J.D. (John), Serruys, P.W.J.C. (Patrick), Sabik, J.F. (Joseph), Dressler, O. (Ovidiu), Crowley, A. (Aaron), Head, S.J. (Stuart), and Kappetein, A.P. (Arie Pieter)
- Abstract
Aim: To evaluate the impact of left ventricular ejection fraction (LVEF) on 3-year outcomes in patients with left main coronary artery disease (LMCAD) undergoing percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) in the EXCEL trial. Methods and results: The EXCEL trial randomized patients with LMCAD to PCI with everolimus-eluting stents (n = 948) or CABG (n = 957). Among 1804 patients with known baseline LVEF, 74 (4.1%) had LVEF <40% [heart failure with reduced ejection fraction (HFrEF)], 152 (8.4%) LVEF 40–49% [heart failure with mid-range ejection fraction (HFmrEF)] and 1578 (87.5%) LVEF ≥50% (heart failure with preserved ejection fraction). Patients with HFrEF vs. HFmrEF vs. preserved LVEF experienced a longer postoperative hospital stay (9.0 vs. 7.0 vs. 6.0 days, P = 0.02) with greater peri-procedural complications after CABG, while hospital stay after PCI was unaffected by LVEF (1.5 vs. 2.0 vs. 1.0 days, P = 0.20). The composite primary endpoint of death, stroke, or myocardial infarction at 3 years was 29.3% (PCI) vs. 27.6% (CABG) in patients with HFrEF, 16.2% vs. 15.0% in patients with HFmrEF, and 14.5% vs. 14.6% in those with preserved LVEF, respectively (Pinteraction = 0.90). Smoothing spline analysis demonstrated that the 3-year risk of all-cause death increased when LVEF decreased, both in patients undergoing CABG and PCI. Conclusion: In the EXCEL trial, the composite rate of death, stroke or myocardial infarction at 3 years was significantly higher in patients with HFrEF compared with HFmrEF or preserved LVEF, driven by an increased rate of all-cause death. No significant differences after PCI vs. CABG were observed among patients with HFrEF, HFmrEF and preserved LVEF. Longer-term follow-up could provide important insights on differences in clinical outcomes that might emerge over time. Clinical Trial Registration: ClinicalTrials.gov ID NCT01205776.
- Published
- 2020
- Full Text
- View/download PDF
18. 10.8 Morphodynamics of Barrier Systems: A Synthesis
- Author
-
McBride, R.A., primary, Anderson, J.B., additional, Buynevich, I.V., additional, Cleary, W., additional, Fenster, M.S., additional, FitzGerald, D.M., additional, Harris, M.S., additional, Hein, C.J., additional, Klein, A.H.F., additional, Liu, B., additional, de Menezes, J.T., additional, Pejrup, M., additional, Riggs, S.R., additional, Short, A.D., additional, Stone, G.W., additional, Wallace, D.J., additional, and Wang, P., additional
- Published
- 2013
- Full Text
- View/download PDF
19. Onyx ONE: outcomes in patients with acute coronary syndrome
- Author
-
Kedhi, E.K, primary, Windecker, S.W, additional, Latib, A, additional, Kandzari, D, additional, Kirtane, A, additional, Mehran, R, additional, Price, M.J, additional, Parke, M, additional, Lung, T, additional, Abizaid, A, additional, Simon, D.I, additional, Worthley, S, additional, Zaman, A, additional, and Stone, G.W, additional
- Published
- 2020
- Full Text
- View/download PDF
20. Wave–sediment interaction on a muddy inner shelf during Hurricane Claudette
- Author
-
Sheremet, A., Mehta, A.J., Liu, B., and Stone, G.W.
- Published
- 2005
- Full Text
- View/download PDF
21. Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention
- Author
-
Sibbing, D. Aradi, D. Alexopoulos, D. ten Berg, J. Bhatt, D.L. Bonello, L. Collet, J.-P. Cuisset, T. Franchi, F. Gross, L. Gurbel, P. Jeong, Y.-H. Mehran, R. Moliterno, D.J. Neumann, F.-J. Pereira, N.L. Price, M.J. Sabatine, M.S. So, D.Y.F. Stone, G.W. Storey, R.F. Tantry, U. Trenk, D. Valgimigli, M. Waksman, R. Angiolillo, D.J.
- Abstract
Dual-antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is the standard treatment for patients undergoing percutaneous coronary intervention. The availability of different P2Y12 receptor inhibitors (clopidogrel, prasugrel, ticagrelor) with varying levels of potency has enabled physicians to contemplate individualized treatment regimens, which may include escalation or de-escalation of P2Y12-inhibiting therapy. Indeed, individualized and alternative DAPT strategies may be chosen according to the clinical setting (stable coronary artery disease vs. acute coronary syndrome), the stage of the disease (early- vs. long-term treatment), and patient risk for ischemic and bleeding complications. A tailored DAPT approach may be potentially guided by platelet function testing (PFT) or genetic testing. Although the routine use of PFT or genetic testing in percutaneous coronary intervention–treated patients is not recommended, recent data have led to an update in guideline recommendations that allow considering selective use of PFT for DAPT de-escalation. However, guidelines do not expand on when to implement the selective use of such assays into decision making for personalized treatment approaches. Therefore, an international expert consensus group of key leaders from North America, Asia, and Europe with expertise in the field of antiplatelet treatment was convened. This document updates 2 prior consensus papers on this topic and summarizes the contemporary updated expert consensus recommendations for the selective use of PFT or genotyping in patients undergoing percutaneous coronary intervention. © 2019 American College of Cardiology Foundation
- Published
- 2019
22. Efficacy and Safety of Stents in ST-Segment Elevation Myocardial Infarction
- Author
-
Chichareon, P., Modolo, R., Collet, C., Tenekecioglu, E., Vink, Matthijs, Oh, P.C., Ahn, J.M., Musto, C., Llera, L.S. Diaz de la, Cho, Y.S., Violini, R., Park, S.J., Suryapranata, H., Piek, J.J., Winter, R.J. de, Wykrzykowska, J.J., Spaulding, C., Kang, W.C., Slagboom, T., Hofma, S.H., Wijnbergen, I.F., Lorenzo, E. Di, Pijls, N.H., Raber, L., Brugaletta, S., Sabate, M., Stoll, H.P., Stone, G.W., Windecker, S., Onuma, Y., Serruys, P.W., Chichareon, P., Modolo, R., Collet, C., Tenekecioglu, E., Vink, Matthijs, Oh, P.C., Ahn, J.M., Musto, C., Llera, L.S. Diaz de la, Cho, Y.S., Violini, R., Park, S.J., Suryapranata, H., Piek, J.J., Winter, R.J. de, Wykrzykowska, J.J., Spaulding, C., Kang, W.C., Slagboom, T., Hofma, S.H., Wijnbergen, I.F., Lorenzo, E. Di, Pijls, N.H., Raber, L., Brugaletta, S., Sabate, M., Stoll, H.P., Stone, G.W., Windecker, S., Onuma, Y., and Serruys, P.W.
- Abstract
Item does not contain fulltext, BACKGROUND: To date, no specific drug-eluting stent (DES) has fully proven its superiority over others in patients with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention. OBJECTIVES: The purpose of this study was to compare the safety and efficacy of coronary artery stents in STEMI patients in a patient-level network meta-analysis. METHODS: Eligible studies were dedicated randomized controlled trials comparing different stents in STEMI patients undergoing percutaneous coronary intervention with at least 12 months of clinical follow-up. Of 19 studies identified from the published data, individual patient data were collected in 15 studies with 10,979 patients representing 87.7% of patients in the overall network of evidence. The primary endpoint was the composite of cardiac death, reinfarction, or target lesion revascularization. RESULTS: Overall, 8,487 (77.3%) of 10,979 STEMI patients were male and the mean age was 60.7 years. At a median follow-up of 3 years, compared with bare-metal stents (BMS), patients treated with paclitaxel-, sirolimus-, everolimus-, or biolimus-eluting stents had a significantly lower risk of the primary endpoint (adjusted hazard ratios [HRs]: 0.74 [95% confidence interval (CI): 0.63 to 0.88], 0.65 [95% CI: 0.49 to 0.85], 0.70 [95% CI: 0.53 to 0.91], and 0.66 [95% CI: 0.49 to 0.88], respectively). The risk of primary endpoint was not different between patients treated with BMS and zotarolimus-eluting stents (adjusted HR: 0.83 [95% CI: 0.51 to 1.38]). Among patients treated with DES, no significant difference in the risk of the primary outcome was demonstrated. Treatment with second-generation DES was associated with significantly lower risk of definite or probable stent thrombosis compared with BMS (adjusted HR: 0.61 [95% CI: 0.42 to 0.89]) and first-generation DES (adjusted HR: 0.56 [95% CI: 0.36 to 0.88]). CONCLUSIONS: In STEMI patients, DES were superior to BMS with respect to long-term effica
- Published
- 2019
23. Stroke After Coronary Artery Bypass Grafting and Percutaneous Coronary Intervention: Incidence, Pathogenesis, and Outcomes
- Author
-
Gaudino, M., Angiolillo, D.J. (Dominick), Di Franco, A., Capodanno, D. (Davide), Bakaeen, F., Farkouh, M.E., Fremes, S.E., Holmes, D., Girardi, L.N., Nakamura, S, Head, S.J. (Stuart), Park, S.-J. (Seung-Jung), Mack, M, Serruys, P.W.J.C. (Patrick), Ruel, M. (Marc), Stone, G.W. (Gregg), Tam, D.Y., Vallely, M., Taggart, D.P. (David), Gaudino, M., Angiolillo, D.J. (Dominick), Di Franco, A., Capodanno, D. (Davide), Bakaeen, F., Farkouh, M.E., Fremes, S.E., Holmes, D., Girardi, L.N., Nakamura, S, Head, S.J. (Stuart), Park, S.-J. (Seung-Jung), Mack, M, Serruys, P.W.J.C. (Patrick), Ruel, M. (Marc), Stone, G.W. (Gregg), Tam, D.Y., Vallely, M., and Taggart, D.P. (David)
- Published
- 2019
- Full Text
- View/download PDF
24. [Accepted Manuscript] Left Main Revascularization With PCI or CABG in Patients With Chronic Kidney Disease: EXCEL Trial
- Author
-
Giustino, G., Mehran, R., Serruys, P.W., Sabik, J.F. 3rd, Milojevic, M., Simonton, C.A., Puskas, J.D., Kandzari, D.E., Morice, M.C., Taggart, D.P., Gershlick, A.H., Généreux, P., Zhang, Z., McAndrew, T., Redfors, B., Ragosta, M. 3rd, Kron, I.L., Dressler, O., Leon, M.B., Pocock, S.J., Ben-Yehuda, O., Kappetein, A.P., and Stone, G.W.
- Abstract
The optimal revascularization strategy for patients with left main coronary artery disease (LMCAD) and chronic kidney disease (CKD) remains unclear. This study investigated the comparative effectiveness of percutaneous coronary intervention (PCI) versus coronary artery bypass graft (CABG) surgery in patients with LMCAD and low or intermediate anatomical complexity according to baseline renal function from the multicenter randomized EXCEL (Evaluation of XIENCE Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization) trial. CKD was defined as an estimated glomerular filtration rate 2 using the CKD Epidemiology Collaboration equation. Acute renal failure (ARF) was defined as a serum creatinine increase ≥5.0 mg/dl from baseline or a new requirement for dialysis. The primary composite endpoint was the composite of death, myocardial infarction (MI), or stroke at 3-year follow-up. CKD was present in 361 of 1,869 randomized patients (19.3%) in whom baseline estimated glomerular filtration rate was available. Patients with CKD had higher 3-year rates of the primary endpoint compared with those without CKD (20.8% vs. 13.5%; hazard ratio [HR]: 1.60; 95% confidence interval [CI]: 1.22 to 2.09; p = 0.0005). ARF within 30 days occurred more commonly in patients with compared with those without CKD (5.0% vs. 0.8%; p interaction = 0.71). There were no significant differences in the rates of the primary composite endpoint after PCI and CABG in patients with CKD (23.4% vs. 18.1%; HR: 1.25; 95% CI: 0.79 to 1.98) and without CKD (13.4% vs. 13.5%; HR: 0.97; 95% CI: 0.73 to 1.27; pinteraction = 0.38). Patients with CKD undergoing revascularization for LMCAD in the EXCEL trial had increased rates of ARF and reduced event-free survival. ARF occurred less frequently after PCI compared with CABG. There were no significant differences between PCI and CABG in terms of death, stroke, or MI at 3 years in patients with and without CKD. (EXCEL Clinical Trial [EXCEL]; NCT01205776).
- Published
- 2018
25. Clinical, Angiographic, and Procedural Correlates of Very Late Absorb Scaffold Thrombosis: Multistudy Registry Results
- Author
-
Ellis, S.G., Gori, T., Serruys, P.W., Nef, H., Steffenino, G., Brugaletta, S., Munzel, T., Feliz, C., Schmidt, G, Sabate, M., Onuma, Y., Geuns, R.J.M. van, Gao, R.L., Menichelli, M., Kereiakes, D.J., Stone, G.W., Testa, L., Kimura, T., and Abizaid, A.
- Subjects
Vascular damage Radboud Institute for Health Sciences [Radboudumc 16] - Abstract
Item does not contain fulltext OBJECTIVES: The aim of this study was to identify independent correlates of very late scaffold thrombosis (VLST) from an analysis of consecutively treated patients from 15 multicenter studies. BACKGROUND: Recent analyses suggest an increased risk for VLST with the Absorb Bioresorbable Vascular Scaffold compared with drug-eluting stents, but insights as to correlates of risk are limited. METHODS: A total of 55 patients were identified with scaffold thrombosis. They were matched 2:1 with control subjects selected randomly from patients without thrombosis from the same study. Quantitative coronary angiography was available for 96.4% of patients. Multiple logistic and Cox regression analysis were used to identify significant independent outcome correlates from 6 pre-specified characteristics. RESULTS: Patients had scaffold thrombosis at a median of 20 months (interquartile range: 17 to 27 months). Control subjects were followed for 36 months (interquartile range: 24 to 38 months). For the combined groups, reference vessel diameter (RVD) was 2.84 +/- 0.50 mm, scaffold length was 26 +/- 16 mm, and post-dilatation was performed in 56%. Univariate correlates of thrombosis were smaller nominal scaffold/RVD ratio (linear p = 0.001; ratio 2.72 mm; odds ratio: 3.4; p = 0.001). Post-dilatation at >/=16 atm, post-dilatation balloon/scaffold ratio, final percentage stenosis, and dual antiplatelet therapy were not correlated with VLST. Only scaffold/RVD ratio remained a significant independent correlate of VLST (p = 0.001), as smaller ratio was correlated with RVD (p < 0.001). Post hoc analysis of 8 other potential covariates revealed no other correlates of outcome. CONCLUSIONS: In the present analysis, the largest to date of its type, relative scaffold undersizing was the strongest determinant of VLST. Given current understanding of "scaffold dismantling," this finding likely has ramifications for all bioresorbable scaffolds.
- Published
- 2018
26. Use of SPD-CD40L to Recruit Immune Cells to the Tumor Microenvironment
- Author
-
Holt, G.E., primary and Stone, G.W., additional
- Published
- 2019
- Full Text
- View/download PDF
27. B-Type Natriuretic Peptide Assessment in Patients Undergoing Revascularization for Left Main Coronary Artery Disease
- Author
-
Redfors, B. (Björn), Chen, S. (Shmuel), Crowley, A. (Aaron), Ben-Yehuda, O. (Ori), Gersh, B.J. (Bernard), Lembo, N.J. (Nicholas J.), Brown, W.M. (W Morris), Banning, A. (Adrian), Taggart, D.P. (David), Serruys, P.W.J.C. (Patrick), Kappetein, A.P. (Arie Pieter), Sabik, J.F. (Joseph), Stone, G.W. (Gregg), Redfors, B. (Björn), Chen, S. (Shmuel), Crowley, A. (Aaron), Ben-Yehuda, O. (Ori), Gersh, B.J. (Bernard), Lembo, N.J. (Nicholas J.), Brown, W.M. (W Morris), Banning, A. (Adrian), Taggart, D.P. (David), Serruys, P.W.J.C. (Patrick), Kappetein, A.P. (Arie Pieter), Sabik, J.F. (Joseph), and Stone, G.W. (Gregg)
- Abstract
BACKGROUND: Elevated B-type natriuretic peptide (BNP) is reflective of impaired cardiac function and is associated with worse prognosis among patients with coronary artery disease (CAD). We sought to assess the association between baseline BNP, adverse outcomes, and the relative efficacy of percutaneous coronary intervention (PCI) versus coronary artery bypass grafting (CABG) in patients with left main CAD. METHODS: The EXCEL trial (Evaluation of XIENCE Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization) randomized patients with left main CAD and low or intermediate SYNTAX scores (Synergy Between PCI With TAXUS and Cardiac Surgery) to PCI with everolimus-eluting stents versus CABG. The primary end point was the composite of all-cause death, myocardial infarction, or stroke. We used multivariable Cox proportional hazards regression to assess the associations between normal versus elevated BNP (≥100 pg/mL), randomized treatment, and the 3-year risk of adverse events. RESULTS: BNP at baseline was elevated in 410 of 1037 (39.5%) patients enrolled in EXCEL. Patients with elevated BNP levels were older and more frequently had additional cardiovascular risk factors and lower left ventricular ejection fraction than those with normal BNP, but had similar SYNTAX scores. Patients with elevated BNP had significantly higher 3-year rates of the primary end point (18.6% versus 11.7%; adjusted hazard ratio [HR], 1.62; 95% confidence interval [CI], 1.16-2.28; P=0.005) and higher mortality (11.5% versus 3.9%; adjusted HR, 2.49; 95% CI, 1.48-4.19; P=0.0006), both from cardiovascular and noncardiovascular causes. In contrast, there were no significant differences in the risks of myocardial infarction, stroke, ischemia-driven revascularization, stent thrombosis, graft occlusion, or major bleeding. A significant interaction ( Pinteraction=0.03) was present between elevated versus normal BNP and treatment with PCI versus CABG for the adjusted risk of th
- Published
- 2018
- Full Text
- View/download PDF
28. Compliance With Guideline-Directed Medical Therapy in Contemporary Coronary Revascularization Trials
- Author
-
Pinho-Gomes, A.-C. (Ana-Catarina), Azevedo, L. (Luis), Ahn, J.-M. (Jung-Min), Park, S.-J. (Seung-Jung), Hamza, T.H. (Taye), Farkouh, M.E. (Michael E.), Serruys, P.W.J.C. (Patrick), Milojevic, M. (Milan), Kappetein, A.P. (Arie Pieter), Stone, G.W. (Gregg), Lamy, A. (André), Fuster, V. (Valentin), Taggart, D.P. (David), Pinho-Gomes, A.-C. (Ana-Catarina), Azevedo, L. (Luis), Ahn, J.-M. (Jung-Min), Park, S.-J. (Seung-Jung), Hamza, T.H. (Taye), Farkouh, M.E. (Michael E.), Serruys, P.W.J.C. (Patrick), Milojevic, M. (Milan), Kappetein, A.P. (Arie Pieter), Stone, G.W. (Gregg), Lamy, A. (André), Fuster, V. (Valentin), and Taggart, D.P. (David)
- Abstract
Background: Despite the well-established benefits of secondary cardiovascular prevention, the importance of concurrent medical therapy in clinical trials of coronary revascularization is often overlooked. Objectives: The goal of this study was to assess compliance with guideline-directed medical therapy (GDMT) in clinical trials and its potential impact on the comparison between percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG). Methods: The Cochrane Central Register of Controlled Trials and MEDLINE were searched from 2005 to August 2017. Clinical trial registries and reference lists of relevant studies were also searched. Randomized controlled trials comparing PCI with drug-eluting stents versus CABG and reporting medical therapy after revascularization were included. The study outcome was compliance with GDMT, defined as the following: 1) any antiplatelet agent plus beta-blocker plus statin (GDMT1); and 2) any antiplatelet agent plus beta-blocker plus statin plus angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (GDMT2). Data collection and analysis were performed according to the methodological recommendations of The Cochrane Collaboration. Results: From a total of 439 references, 5 trials were included based on our inclusion and exclusion criteria. Overall, compliance with GDMT1 was low and decreased over time from 67% at 1 year to 53% at 5 years. Compliance with GDMT2 was even lower and decreased from 40% at 1 year to 38% at 5 years. Compliance with both GDMT1 and GDMT2 was higher in PCI than in CABG at all time points. Meta-regression suggested an association between lower use of GDMT1 and adverse clinical outcomes in PCI versus CABG at 5 years. Conclusions: Compliance with GDMT in contemporary clinical trials remains suboptimal and is significantly lower after CABG than after PCI, which may influence the comparison of clinical trial endpoints between those study groups.
- Published
- 2018
- Full Text
- View/download PDF
29. New-Onset Atrial Fibrillation After PCI or CABG for Left Main Disease: The EXCEL Trial
- Author
-
Kosmidou, I. (Ioanna), Chen, S. (Shmuel), Kappetein, A.P. (Arie Pieter), Serruys, P.W.J.C. (Patrick), Gersh, B.J. (Bernard), Puskas, J.D. (John), Kandzari, D.E. (David), Taggart, D.P. (David), Morice, M-C. (Marie-Claude), Buszman, P.E. (Pawel), Bochenek, A. (Andrzej), Schampaert, E. (Erick), Pagé, P. (Pierre), Sabik, J.F. (Joseph), McAndrew, T.C. (Thomas), Redfors, B. (Björn), Ben-Yehuda, O. (Ori), Stone, G.W. (Gregg), Kosmidou, I. (Ioanna), Chen, S. (Shmuel), Kappetein, A.P. (Arie Pieter), Serruys, P.W.J.C. (Patrick), Gersh, B.J. (Bernard), Puskas, J.D. (John), Kandzari, D.E. (David), Taggart, D.P. (David), Morice, M-C. (Marie-Claude), Buszman, P.E. (Pawel), Bochenek, A. (Andrzej), Schampaert, E. (Erick), Pagé, P. (Pierre), Sabik, J.F. (Joseph), McAndrew, T.C. (Thomas), Redfors, B. (Björn), Ben-Yehuda, O. (Ori), and Stone, G.W. (Gregg)
- Abstract
Background: There is limited information on the incidence and prognostic impact of new-onset atrial fibrillation (NOAF) following percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) for left main coronary artery disease (LMCAD). Objectives: This study sought to determine the incidence of NOAF following PCI and CABG for LMCAD and its effect on 3-year cardiovascular outcomes. Methods: In the EXCEL (Evaluation of XIENCE Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization) trial, 1,905 patients with LMCAD and low or intermediate SYNTAX scores were randomized to PCI with everolimus-eluting stents versus CABG. Outcomes were analyzed according to the development of NOAF during the initial hospitalization following revascularization. Results: Among 1,812 patients without atrial fibrillation on presentation, NOAF developed at a mean of 2.7 ± 2.5 days after revascularization in 162 patients (8.9%), including 161 of 893 (18.0%) CABG-treated patients and 1 of 919 (0.1%) PCI-treated patients (p < 0.0001). Older age, greater body mass index, and reduced left ventricular ejection fraction were independent predictors of NOAF in patients undergoing CABG. Patients with versus without NOAF had a significantly longer duration of hospitalization, were more likely to be discharged on anticoagulant therapy, and had an increased 30-day rate of Thrombolysis In Myocardial Infarction major or minor bleeding (14.2% vs. 5.5%; p < 0.0001). By multivariable analysis, NOAF after CABG was an independent predictor of 3-year stroke (6.6% vs. 2.4%; adjusted hazard ratio [HR]: 4.19; 95% confidence interval [CI]: 1.74 to 10.11; p = 0.001), death (11.4% vs. 4.3%; adjusted HR: 3.02; 95% CI: 1.60 to 5.70; p = 0.0006), and the primary composite endpoint of death, MI, or stroke (22.6% vs. 12.8%; adjusted HR: 2.13; 95% CI: 1.39 to 3.25; p = 0.0004). Conclusions: In patients with LMCAD undergoing revascularization in the EXCEL trial, NOAF was c
- Published
- 2018
- Full Text
- View/download PDF
30. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials
- Author
-
Costa, F., Klaveren, D. van, James, S., Heg, D., Raber, L., Feres, F., Pilgrim, T., Hong, M.K., Kim, H.S., Colombo, A., Steg, P.G., Zanchin, T., Palmerini, T., Wallentin, L., Bhatt, D.L., Stone, G.W., Windecker, S., Steyerberg, E.W., Valgimigli, M., and PRECISE-DAPT Study Investigators
- Subjects
610 Medicine & health ,360 Social problems & social services - Abstract
BACKGROUND Dual antiplatelet therapy (DAPT) with aspirin plus a P2Y12 inhibitor prevents ischaemic events after coronary stenting, but increases bleeding. Guidelines support weighting bleeding risk before the selection of treatment duration, but no standardised tool exists for this purpose. METHODS A total of 14 963 patients treated with DAPT after coronary stenting-largely consisting of aspirin and clopidogrel and without indication to oral anticoagulation-were pooled at a single-patient level from eight multicentre randomised clinical trials with independent adjudication of events. Using Cox proportional hazards regression, we identified predictors of out-of-hospital Thrombosis in Myocardial Infarction (TIMI) major or minor bleeding stratified by trial, and developed a numerical bleeding risk score. The predictive performance of the novel score was assessed in the derivation cohort and validated in patients treated with percutaneous coronary intervention from the PLATelet inhibition and patient Outcomes (PLATO) trial (n=8595) and BernPCI registry (n=6172). The novel score was assessed within patients randomised to different DAPT durations (n=10 081) to identify the effect on bleeding and ischaemia of a long (12-24 months) or short (3-6 months) treatment in relation to baseline bleeding risk. FINDINGS The PRECISE-DAPT score (age, creatinine clearance, haemoglobin, white-blood-cell count, and previous spontaneous bleeding) showed a c-index for out-of-hospital TIMI major or minor bleeding of 0·73 (95% CI 0·61-0·85) in the derivation cohort, and 0·70 (0·65-0·74) in the PLATO trial validation cohort and 0·66 (0·61-0·71) in the BernPCI registry validation cohort. A longer DAPT duration significantly increased bleeding in patients at high risk (score ≥25), but not in those with lower risk profiles (pinteraction=0·007), and exerted a significant ischaemic benefit only in this latter group. INTERPRETATION The PRECISE-DAPT score is a simple five-item risk score, which provides a standardised tool for the prediction of out-of-hospital bleeding during DAPT. In the context of a comprehensive clinical evaluation process, this tool can support clinical decision making for treatment duration. FUNDING None.
- Published
- 2017
31. Time course, predictors and clinical implications of stent thrombosis following primary angioplasty
- Author
-
Luca, G. de, Dirksen, M.T., Spaulding, C., Kelbaek, H., Schalij, M., Thuesen, L., Hoeven, B. van der, Vink, M.A., Kaiser, C., Musto, C., Chechi, T., Spaziani, G., Llera, L.S.D. de la, Pasceri, V., Lorenzo, E. di, Violini, R., Suryapranata, H., Stone, G.W., and DESERT Cooperation
- Subjects
Male ,medicine.medical_specialty ,Time Factors ,Databases, Factual ,medicine.medical_treatment ,Acute myocardial infarction ,030204 cardiovascular system & hematology ,03 medical and health sciences ,Percutaneous Coronary Intervention ,0302 clinical medicine ,Predictive Value of Tests ,Risk Factors ,Internal medicine ,Diabetes mellitus ,medicine ,Humans ,clinical studies ,030212 general & internal medicine ,Myocardial infarction ,thrombosis ,Aged ,Randomized Controlled Trials as Topic ,Cardiovascular diseases [NCEBP 14] ,business.industry ,Angioplasty ,Percutaneous coronary intervention ,Stent ,Drug-Eluting Stents ,Hematology ,Thrombolysis ,Middle Aged ,Prognosis ,medicine.disease ,Survival Analysis ,Thrombosis ,Surgery ,Cardiology ,Population study ,Female ,business ,Blood Flow Velocity ,TIMI ,Follow-Up Studies - Abstract
summaryPrimary percutaneous coronary intervention (pPCI) has improved survival as compared to thrombolysis. Concerns still remain regarding the risk of stent thrombosis in the setting of STEMI, especially after drugeluting stent (DES) implantation. Therefore, the aim of this study was to report on the timing of stent thrombosis (ST) with both DES and bare metal stents (BMS) and its prognostic significance in patients undergoing pPCI. The Drug-Eluting Stent in Primary Angioplasty (DESERT) cooperation is based on a pooled database including individual data of randomised trials that evaluate the long-term safety and effectiveness of DES as compared to BMS in patients undergoing pPCI for STEMI. Follow-up data were collected for 3–6 years after the procedure. ST was defined as definite or probable, based on the ARC definition. The study population consists of 6,274 STEMI patients undergoing primary angioplasty with BMS or DES. At 1201±440 days, ST occurred in 267 patients (4.25%). Most of the events were acute or subacute (within 30 days) and very late (> 1 years), with different distribution between DES vs BMS. Patients with ST were more often diabetic (21.7% vs 15.1%, p=0.005), more frequently had post-procedural TIMI 0–2 flow (14.0% vs 9.3%, p = 0.01), and were less often treated with dual antiplatelet therapy at one year follow-up. Diabetes (p = 0.036), post-procedural TIMI 0–2 Flow (p = 0.013) and ischaemia time > 6 hours (p = 0.03) were independent predictors of ST. Post-procedural TIMI 0–2 flow (p = 0.001) and ischaemia time > 6 hours (p < 0.001) were independent predictors of early ST, ischaemia time > 6 hours (p=0.05) was independent predictor of late ST, whereas diabetes (p = 0.022) and use of DES (p=0.002) were independent predictors of very late ST. ST was associated with a significantly higher mortality (23.6% vs 6%, p < 0.001). The greatest impact on mortality was observed with subacute (40.4%) and late (20.9%) ST, as compared to acute (12.5%) and very late (9.1%) ST. ST was an independent predictor of mortality (HR [95%CI]=3.73 [2.75–5.07], p < 0.001). In conclusion, ST occurs relatively frequently also beyond the first year for up to six years after pPCI in STEMI, with higher late occurrence rates among patients treated with first generation DES. ST after pPCI is a powerful predictor of mortality, especially subacute ST.
- Published
- 2013
32. Clinical, Angiographic, and Procedural Correlates of Acute, Subacute, and Late Absorb Scaffold Thrombosis
- Author
-
Ellis, S.G., Steffenino, G., Kereiakes, D.J., Stone, G.W., Geuns, R.J.M. van, Abizaid, A., Nef, H., Cortese, B., Testa, L., Menichelli, M., Tamburino, C., Gori, T., Kimura, T., Serruys, P.W., Brugaletta, S., Sabate, M., Gao, R.L., Ellis, S.G., Steffenino, G., Kereiakes, D.J., Stone, G.W., Geuns, R.J.M. van, Abizaid, A., Nef, H., Cortese, B., Testa, L., Menichelli, M., Tamburino, C., Gori, T., Kimura, T., Serruys, P.W., Brugaletta, S., Sabate, M., and Gao, R.L.
- Abstract
Item does not contain fulltext, OBJECTIVES: The authors sought to identify and verify independent correlates of device thrombosis from an analysis of multicenter trials and registries. BACKGROUND: Recent analyses suggest an increased risk of device thrombosis with Absorb bioresorbable vascular scaffold (Abbott Vascular, Santa Clara, California) implantation compared with metallic drug-eluting stents, and data from moderate size studies suggest a risk relationship to vessel size and technique. METHODS: From 8,771 consecutively treated patients, 105 patients (1.2%) were identified with scaffold thrombosis within 1 year of implantation. They were matched 2:1 with controls selected randomly from nonthrombosis patients. Data-restricted multiple logistic analysis was used to identify significant independent covariates of the outcome. RESULTS: Early (within 1 month) scaffold thrombosis occurred in 69 patients and late (1 to 12 months) thrombosis occurred in 36 patients. Modelling found significant correlations of thrombosis to be final minimal lumen diameter <1.85 mm (odds ratio [OR]: 3.1; p = 0.004), off dual antiplatelet therapy (DAPT) status (OR: 3.1 to 3.5; p = 0.006 to 0.053), no post-dilatation with >1.1:1 balloon/scaffold ratio (OR: 2.3; p = 0.022), and reference vessel diameter <2.40 mm (OR: 2.1; p = 0.036). CONCLUSIONS: Suboptimal vessel sizing, procedural technique, angiographic outcomes, and dual antiplatelet therapy discontinuation appear to be the principal determinants of Absorb scaffold thrombosis risk through 12 months after implantation.
- Published
- 2017
33. First-in-Human Evaluation of a Novel Polymer-Free Drug-Filled Stent: Angiographic, IVUS, OCT, and Clinical Outcomes From the RevElution Study.
- Author
-
Meredith I., Worthley S.G., Kirtane A.J., Meredith I.T., Simon D.I., Windecker S., Brar S., Almonacid A.P., Chamie D., Maehara A., Stone G.W., Worthley S., Shetty S., Sinhal A., Abizaid A., Jepson N., Bhindi R., Lim S.T., Stewart P., Barlis P., Walters D., Muller D., Cox S., Bhagwandeen R., Meredith I., Worthley S.G., Kirtane A.J., Meredith I.T., Simon D.I., Windecker S., Brar S., Almonacid A.P., Chamie D., Maehara A., Stone G.W., Worthley S., Shetty S., Sinhal A., Abizaid A., Jepson N., Bhindi R., Lim S.T., Stewart P., Barlis P., Walters D., Muller D., Cox S., and Bhagwandeen R.
- Abstract
Objectives This study sought to assess the safety and effectiveness of the drug-filled stent (DFS) (Medtronic, Santa Rosa, California) in the treatment of patients with coronary artery disease. Background Polymer-free drug-eluting stents have the potential to improve clinical outcomes and facilitate shorter durations of dual antiplatelet therapy. The polymer-free DFS is made from a trilayered continuous wire with an outer cobalt chromium layer, a middle tantalum layer, and an inner lumen coated with sirolimus. Small laser-drilled holes on the abluminal stent surface control drug elution. Methods The RevElution trial enrolled 100 patients with de novo coronary lesions 2.25 to 3.50 mm in diameter and length <=27 mm in 2 cohorts of 50 patients for angiographic, intravascular ultrasound, and clinical assessment at 9 or 24 months, with optical coherence tomography performed in a subset of 30 patients at each time period. The primary endpoint was angiographic in-stent late lumen loss at 9 months compared with Resolute zotarolimus-eluting stent (Medtronic) historical control data. Results Fifty patients with 56 lesions were treated with DFS in the 9-month cohort. In-stent late lumen loss was 0.26 +/- 0.28 mm for DFS and 0.36 +/- 0.52 mm for Resolute (pnoninferiority <0.001). The binary angiographic restenosis rate was 0%. Median stent strut coverage by optical coherence tomography was 91.4%, 95.6%, and 99.1% at 1, 3, and 9 months, respectively. One non-Q-wave myocardial infarction occurred, with a 9-month target lesion failure rate of 2.1%. No stent thrombosis occurred. Conclusions At 9 months, the polymer-free DFS was safe and effective with high rates of early strut coverage and noninferior late lumen loss compared to Resolute. (Medtronic RevElution Trial [RevElution]; NCT02480348)Copyright © 2017 The Authors
- Published
- 2017
34. Long-Term Safety and Efficacy of Platinum Chromium Everolimus-Eluting Stents in Coronary Artery Disease: 5-Year Results From the PLATINUM Trial.
- Author
-
Carrie D., Hagiwara N., Rabinowitz A., Pompili V., Stone G.W., Dawkins K.D., Allocco D.J., Saito S., Bouchard A., Kelly C.R., Teirstein P.S., Meredith I.T., Farah B., Dubois C.L., Feldman R.L., Dens J., Carrie D., Hagiwara N., Rabinowitz A., Pompili V., Stone G.W., Dawkins K.D., Allocco D.J., Saito S., Bouchard A., Kelly C.R., Teirstein P.S., Meredith I.T., Farah B., Dubois C.L., Feldman R.L., and Dens J.
- Abstract
Objectives The authors sought to evaluate the final 5-year safety and effectiveness of the platinum-chromium everolimus-eluting stent (PtCr-EES) in the randomized trial, as well as in 2 single-arm substudies that evaluated PtCr-EES in small vessels (diameter <2.5 mm; n = 94) and long lesions (24 to 34 mm; n = 102). Background In the multicenter, randomized PLATINUM (PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions), the PtCr-EES was noninferior to the cobalt-chromium everolimus-eluting stent (CoCr-EES) at 1 year in 1,530 patients undergoing percutaneous coronary intervention. Methods Patients with 1 or 2 de novo coronary artery lesions (reference vessel diameter 2.50 to 4.25 mm, length <=24 mm) were randomized 1:1 to PtCr-EES versus CoCr-EES. All patients in the substudies received PtCr-EES. The primary endpoint was target lesion failure (TLF), a composite of target vessel-related cardiac death, target vessel-related myocardial infarction, or ischemia-driven target lesion revascularization. Results In the randomized trial, the 5-year TLF rate was 9.1% for PtCr-EES and 9.3% for CoCr-EES (hazard ratio [HR]: 0.97; p = 0.87). Landmark analysis demonstrated similar TLF rates from discharge to 1 year (HR: 1.12; p = 0.70) and from 1 to 5 years (HR: 0.90; p = 0.63). There were no significant differences in the rates of cardiac death, myocardial infarction, target lesion or vessel revascularization, or stent thrombosis. PtCr-EES had 5-year TLF rates of 7.0% in small vessels and 13.6% in long lesions. Conclusions PtCr-EES demonstrated comparable safety and effectiveness to CoCr-EES through 5 years of follow-up, with low rates of stent thrombosis and other adverse events. The 5-year event rates were also acceptable in patients with small vessels and long lesions treated with PtCr-EES. (The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions [PLATINUM
- Published
- 2017
35. Global position paper on cardiovascular regenerative medicine
- Author
-
Fernández-Avilés, F. (Francisco), Sanz-Ruiz, R. (Ricardo), Climent, A.M. (Andreu M.), Badimon, L. (Lina), Bolli, R. (Roberto), Charron, D. (Dominique), Fuster, V. (Valentin), Janssens, S. (Stefan), Kastrup, J. (Jens), Kim, H.-S. (Hyo-Soo), Lüscher, T.F., Martin, J.F. (John F.), Menasche, P. (Philippe), Simari, P. (Patricio), Stone, G.W. (Gregg), Terzic, A. (Andre), Willerson, J.T. (James), Wu, J.C. (Joseph C.), Joseph, C.W. (C. Wu), Broughton, K. (Kathleen), DiFede, D.L. (Darcy L.), Dimmeler, S. (Stefanie), Madonna, R. (Rosalinda), Penn, M.S. (Marc S.), Sussman, M.A. (Mark A.), Sluijter, J.P.G., Woller, K.C. (Kai C.), Balkan, W. (Wayne), Chamuleau, S.A.J. (Steven), Fernández-Santos, M.E. (Maria Eugenia), Goliasch, G. (Georg), Gyöngyösi, M. (Mariann), Hare, J.M. (Joshua M.), Tompkins, B.A. (Bryon A.), Winkler, J. (Johannes), Bayés-Genis, A. (Antoni), Henry, T.D. (Timothy), Taylor, D.A. (Doris), Lerman, A. (Amir), Pelacho, B. (Beatriz), Prosper, F. (Felipe), Perin, E.C. (Emerson ), Pompilio, G. (Giulio), Gersh, B.J. (Bernard), Bartúnek, J. (Jozef), Duckers, E. (Eric), Ferdinandy, P. (Péter), Losordo, D.W. (Douglas W.), Čanchez, P.L. (Pedro L.), Sherman, W. (Warren), Wojakowski, W. (Wojtek), Zeiher, A.M. (Andreas), Roncalli, J. (Jérôme), Mathur, A. (Anthony), Crea, F. (Filippo), D'Amario, D. (Domenico), Povsic, T.J. (Thomas J.), Traverse, J.H. (Jay), Ylä-Herttuala, S. (Seppo), Fernández-Avilés, F. (Francisco), Sanz-Ruiz, R. (Ricardo), Climent, A.M. (Andreu M.), Badimon, L. (Lina), Bolli, R. (Roberto), Charron, D. (Dominique), Fuster, V. (Valentin), Janssens, S. (Stefan), Kastrup, J. (Jens), Kim, H.-S. (Hyo-Soo), Lüscher, T.F., Martin, J.F. (John F.), Menasche, P. (Philippe), Simari, P. (Patricio), Stone, G.W. (Gregg), Terzic, A. (Andre), Willerson, J.T. (James), Wu, J.C. (Joseph C.), Joseph, C.W. (C. Wu), Broughton, K. (Kathleen), DiFede, D.L. (Darcy L.), Dimmeler, S. (Stefanie), Madonna, R. (Rosalinda), Penn, M.S. (Marc S.), Sussman, M.A. (Mark A.), Sluijter, J.P.G., Woller, K.C. (Kai C.), Balkan, W. (Wayne), Chamuleau, S.A.J. (Steven), Fernández-Santos, M.E. (Maria Eugenia), Goliasch, G. (Georg), Gyöngyösi, M. (Mariann), Hare, J.M. (Joshua M.), Tompkins, B.A. (Bryon A.), Winkler, J. (Johannes), Bayés-Genis, A. (Antoni), Henry, T.D. (Timothy), Taylor, D.A. (Doris), Lerman, A. (Amir), Pelacho, B. (Beatriz), Prosper, F. (Felipe), Perin, E.C. (Emerson ), Pompilio, G. (Giulio), Gersh, B.J. (Bernard), Bartúnek, J. (Jozef), Duckers, E. (Eric), Ferdinandy, P. (Péter), Losordo, D.W. (Douglas W.), Čanchez, P.L. (Pedro L.), Sherman, W. (Warren), Wojakowski, W. (Wojtek), Zeiher, A.M. (Andreas), Roncalli, J. (Jérôme), Mathur, A. (Anthony), Crea, F. (Filippo), D'Amario, D. (Domenico), Povsic, T.J. (Thomas J.), Traverse, J.H. (Jay), and Ylä-Herttuala, S. (Seppo)
- Published
- 2017
- Full Text
- View/download PDF
36. Impact of TCFA on Unanticipated Ischemic Events in Medically Treated Diabetes Mellitus: Insights From the PROSPECT Study
- Author
-
Kedhi, E. (Elvin), Kennedy, M.W. (Mark W.), Maehara, A. (Akiko), Lansky, A.J. (Alexandra), McAndrew, T.C. (Thomas), Marso, S.P. (Steven), Bruyne, B. (Bernard) de, Serruys, P.W.J.C. (Patrick), Stone, G.W. (Gregg), Kedhi, E. (Elvin), Kennedy, M.W. (Mark W.), Maehara, A. (Akiko), Lansky, A.J. (Alexandra), McAndrew, T.C. (Thomas), Marso, S.P. (Steven), Bruyne, B. (Bernard) de, Serruys, P.W.J.C. (Patrick), and Stone, G.W. (Gregg)
- Abstract
Objectives This study sought to investigate the relationship between thin-cap fibroatheromas (TCFAs) on major adverse cardiac events (MACEs) arising from medically treated nonculprit lesions (NCLs) in patients with acute coronary syndromes (ACS) with and without diabetes mellitus (DM). Background MACEs occur frequently in patients with DM and ACS. The impact of plaque composition on subsequent MACEs in DM patients with ACS is unknown. Methods In the PROSPECT (Providing Regional Observations Study Predictors of Events in the Coronary Tree) study, using 3-vessel radiofrequency intravascular ultrasound, we analyzed the incidence of NCL-MACE in 2 propensity-matched groups according to the presence of DM and TCFA. Results Among 697 patients, 119 (17.7%) had DM. The 3-year total MACE rate (29.4% vs. 18.8%; p = 0.01) was significantly higher in patients with versus without DM, driven by a higher rate of NCL-MACE in DM (18.7% vs. 10.4%; p = 0.02). Propensity score matching generated 2 balanced groups with and without DM of 82 patients each. Among DM patients, the presence of ≥1 TCFA was associated with higher NCL-MACE at 3 years (27.8% vs. 8.9% in patients without a TCFA, hazard ratio: 3.56; 95% confidence interval: 0.98 to 12.96; p = 0.04). DM patients without a TCFA had a similar 3-year rate of NCL-MACE as patients without DM (8.9% vs. 8.9%; hazard ratio: 1.09; 95% confidence interval: 0.27 to 4.41; p = 0.90). Conclusions ACS patients with DM and ≥1 TCFA have a high rate of NCL-MACE at 3 years. In contrast, the prognosis of ACS patients with DM but no TCFAs is favorable and similar to patients without DM.
- Published
- 2017
- Full Text
- View/download PDF
37. Prediction of atherosclerotic disease progression using LDL transportmodelling: A serial computed tomographic coronary angiographic study
- Author
-
Sakellarios, A.I. (Antonis), Bourantas, C.V. (Christos), Papadopoulou, S.L. (Stella-Lida), Tsirka, Z. (Zeta), Vries, T. (Ton) de, Kitslaar, P.H. (Pieter), Girasis, C. (Chrysafios), Naka, K.K. (Katerina), Fotiadis, D.I. (Dimitrios), Veldhof, S. (Susan), Stone, G.W. (Greg W.), Reiber, J.H.C. (Johan), Michalis, L.K. (Lampros), Serruys, P.W.J.C. (Patrick), De Feyter, P.J. (Pim J.), Garcia-Garcia, H.M. (Hector), Sakellarios, A.I. (Antonis), Bourantas, C.V. (Christos), Papadopoulou, S.L. (Stella-Lida), Tsirka, Z. (Zeta), Vries, T. (Ton) de, Kitslaar, P.H. (Pieter), Girasis, C. (Chrysafios), Naka, K.K. (Katerina), Fotiadis, D.I. (Dimitrios), Veldhof, S. (Susan), Stone, G.W. (Greg W.), Reiber, J.H.C. (Johan), Michalis, L.K. (Lampros), Serruys, P.W.J.C. (Patrick), De Feyter, P.J. (Pim J.), and Garcia-Garcia, H.M. (Hector)
- Abstract
Aim To investigate the efficacy of low-density lipoprotein (LDL) transport simulation in reconstructed arteries derived from computed tomography coronary angiography (CTCA) to predict coronary segments that are prone to progress. Methods and results Thirty-Two patients admitted with an acute coronary event who underwent 64-slice CTCA after percutaneous coronary intervention and at 3-year follow-up were included in the analysis. The CTCA data were
- Published
- 2017
- Full Text
- View/download PDF
38. Impact of lesion calcification on angiographic outcomes after Absorb everolimus-eluting bioresorbable vascular scaffold implantation: An observation from the ABSORB Japan trial
- Author
-
Ohya, M. (Masanobu), Kadota, K. (Kazushige), Sotomi, Y. (Yohei), Kozuma, K. (Ken), Tanabe, K. (Kengo), Uematsu, M. (Masaaki), Kawasaki, T. (Tomohiro), Morino, Y. (Yoshihiro), Tobaru, T. (Tetsuya), Nakao, K. (Koichi), Tachibana, K. (Kouichi), Kishi, K. (Koichi), Shibata, Y. (Yoshisato), Ying, S. (Shihwa), Kusano, H. (Hajime), Stone, G.W. (Gregg), Popma, J.J. (Jeffrey), Onuma, Y. (Yoshinobu), Serruys, P.W.J.C. (Patrick), Kimura, T. (Takeshi), Ohya, M. (Masanobu), Kadota, K. (Kazushige), Sotomi, Y. (Yohei), Kozuma, K. (Ken), Tanabe, K. (Kengo), Uematsu, M. (Masaaki), Kawasaki, T. (Tomohiro), Morino, Y. (Yoshihiro), Tobaru, T. (Tetsuya), Nakao, K. (Koichi), Tachibana, K. (Kouichi), Kishi, K. (Koichi), Shibata, Y. (Yoshisato), Ying, S. (Shihwa), Kusano, H. (Hajime), Stone, G.W. (Gregg), Popma, J.J. (Jeffrey), Onuma, Y. (Yoshinobu), Serruys, P.W.J.C. (Patrick), and Kimura, T. (Takeshi)
- Abstract
Aims: We aimed to investigate the impact of lesion calcification on angiographic outcomes after Absorb everolimus-eluting bioresorbable vascular scaffold (BVS) implantation in comparison with those after cobalt-chromium everolimus-eluting stent (CoCr-EES) implantation. Methods and results: The present post hoc analysis of the ABSORB Japan randomised trial compared post-procedure and 13-month angiographic outcomes between patients implanted with BVS and CoCr-EES based on the presence or absence of calcification, excluding extremely heavily calcified lesions or lesions requiring rotational atherectomy. The study population comprised 384 patients with 384 lesions (including 114 lesions [29.7%] with moderate or severe calcification), classified into two subgroups: calcification, 114 (BVS: n=72 and CoCr-EES: n=42) and non-calcification, 270 (BVS: n=181 and CoCr-EES: n=89). Follow-up angiography was performed in 94.8% of patients. Both post-procedure and follow-up indevice minimal lumen diameters were comparable in both the BVS arm (calcification vs. non-calcification: 2.43±0.32 mm vs. 2.43±0.39 mm, p=0.91 and 2.17±0.49 mm vs. 2.27±0.47 mm, p=0.17) and in the CoCr-EES arm (2.68±0.34 mm vs. 2.65±0.42 mm, p=0.62 and 2.57±0.52 mm vs. 2.47±0.53 mm, p=0.36). Conclusions: Moderate or severe lesion calcification (excluding patients with extremely heavily calcified lesions or lesions requiring rotational atherectomy) does not negatively affect angiographic outcomes at both post-procedure and 13-month follow-up after BVS implantation.
- Published
- 2017
- Full Text
- View/download PDF
39. Everolimus eluting stent vs first generation drug-eluting stent in primary angioplasty: A pooled patient-level meta-analysis of randomized trials
- Author
-
Luca, G. De, Smits, Peter, Hofma, S.H., Lorenzo, E. Di, Vlachojannis, G.J., Hof, A.W. van 't, Boven, A.J. van, Kedhi, E., Stone, G.W., Suryapranata, H., Luca, G. De, Smits, Peter, Hofma, S.H., Lorenzo, E. Di, Vlachojannis, G.J., Hof, A.W. van 't, Boven, A.J. van, Kedhi, E., Stone, G.W., and Suryapranata, H.
- Abstract
Item does not contain fulltext, BACKGROUND: Several concerns have emerged about the higher risk of very late stent thrombosis (ST) with first generation drug-eluting stent (DES) especially among STEMI patients. Newer generation DES has demonstrated to reduce ST at mid-term follow-up. Therefore, the aim of the present study is to perform an individual patient's data meta-analysis of trials comparing 1st generation DES vs. 2nd generation DES (everolimus-eluting stent, EES) in patients undergoing primary percutaneous coronary intervention (PCI) for STEMI. METHODS: We performed a formal search of electronic databases (MEDLINE and CENTRAL) and scientific session presentations from January 2010 to June 2016. We included all completed randomized trials comparing 1st vs. EES for patient presenting with STEMI. RESULTS: Individual patients data were obtained from 3 trials, including a total of 1581 patients (686 or 43.4% randomized to 1st generation DES and 895 or 56.4% randomized to EES). At long-term follow-up (1584+/-588days), EES did not significantly reduce mortality (7.8.% vs 11.7%, HR [95%CI]=0.77 [0.52, 1.13], p=0.18, pheterogeneity=0.93), cardiac mortality (6.2% vs 7.6%, HR [95%CI]=0.90 [0.56, 1.44], p=0.65, pheterogeneity=0.85), and reinfarction (8.1% versus 11.2%, respectively; HR [95%CI]=0.74 [0.51, 1.07], p=0.11, pheterogeneity=0.52). However, EES significantly reduced the occurrence of ST (3.4% versus 6.1% respectively, HR [95%CI]=0.56 [0.32, 0.97], p=0.04, pheterogeneity=0.42) and target vessel revascularization (TVR) (14.2% versus 20.1%; HR [95%CI]=0.63 [0.42, 0.96], p=0.03, pheterogeneity=0.55). Landmark analysis showed more consistent benefits in ST with EES within 1year, whereas benefits in TVR were mostly observed later than 1year. CONCLUSIONS: The present pooled patient-level meta-analysis demonstrates that among STEMI patients undergoing primary PCI, EES as compared to 1st generation DES is associated with a significant reduction in ST and TVR at long-term follow-up.
- Published
- 2017
40. Peri-infarct zone pacing to prevent adverse left ventricular remodelling in patients with large myocardial infarction
- Author
-
Stone, G.W., Chung, E.S., Stancak, B., Svendsen, J.H., Fischer, T.M., Kueffer, F., Ryan, T., Bax, J., Leon, A., and PRomPT Trial Investigators
- Subjects
Male ,medicine.medical_specialty ,Diastole ,Infarction ,Heart failure ,030204 cardiovascular system & hematology ,Cardiac Resynchronization Therapy ,03 medical and health sciences ,QRS complex ,0302 clinical medicine ,Internal medicine ,Clinical endpoint ,Medicine ,Humans ,030212 general & internal medicine ,Myocardial infarction ,Prospective Studies ,Ejection fraction ,Ventricular End-Systolic Volume ,Ventricular Remodeling ,business.industry ,Stroke Volume ,Middle Aged ,medicine.disease ,Prognosis ,Treatment Outcome ,Left ventricular remodelling ,Cardiology ,Female ,Cardiology and Cardiovascular Medicine ,business - Abstract
Aims We sought to determine whether peri-infarct pacing prevents left ventricular (LV) remodelling and improves functional and clinical outcomes in patients with large first myocardial infarction (MI). Methods and results A total of 126 patients at 27 international sites within 10 days of onset of anterior or non-anterior MI with creatine phosphokinase >3000 U/L and QRS duration ≤120 ms were randomized 1:1:1 to dual-site biventricular pacing vs. single-site LV only pacing vs. non-implanted control. The primary endpoint was the echocardiographic core laboratory-assessed change in LV end-diastolic volume (ΔLVEDV) from baseline to 18 months between the pooled pacing therapy groups and the control group. ΔLVEDV increased by 15.3 ± 28.6 mL in the control group and by 16.7 ± 30.5 mL in the pooled pacing groups during follow-up (adjusted mean difference (95% CI) = 0.6 (−12.3, 13.5) mL, P = 0.92). There were also no significant between-group differences in the change in LV end-systolic volume or ejection fraction over time. Quality of life, as assessed by the Minnesota Living with Heart Failure (HF) and European Quality of Life-5 Dimension questionnaires and New York Heart Association class, was also similar between groups during 18-month follow-up. Six-minute walk distance improved during follow-up to an equal degree between groups, and there were no significant differences in the 18-month rates of death or HF hospitalization between the pooled pacing therapy vs. control groups (17.4 vs. 21.7% respectively, P = 0.59). Conclusions In the present multicentre, randomized trial, peri-infarct pacing did not prevent LV remodelling or improve functional or clinical outcomes during 18-month follow-up in patients with large first MI. ClinicalTrials.gov identifier NCT01213251.
- Published
- 2016
41. Hemodynamic, Functional, and Clinical Responses to Pulmonary Artery Denervation in Patients With Pulmonary Arterial Hypertension of Different Causes: Phase II Results From the Pulmonary Artery Denervation-1 Study
- Author
-
Chen, S-L., Zhang, H., Xie, D-J., Zhang, J., Zhou, L., Rothman, A.M.K., and Stone, G.W.
- Abstract
Background—The mechanisms underlying pulmonary arterial hypertension (PAH) are multifactorial. The efficacy of\ud pulmonary artery denervation (PADN) for idiopathic PAH treatment has been evaluated. This study aimed to analyze the\ud hemodynamic, functional, and clinical responses to PADN in patients with PAH of different causes.\ud Methods and Results—Between April 2012 and April 2014, 66 consecutive patients with a resting mean pulmonary arterial\ud pressure ≥25 mmHg treated with PADN were prospectively followed up. Target drugs were discontinued after the PADN\ud procedure. Hemodynamic response and 6-minute walk distance were repeatedly measured within the 1 year post PADN\ud follow-up. The clinical end point was the occurrence of PAH-related events at the 1-year follow-up. There were no PADNrelated\ud complications. Hemodynamic success (defined as the reduction in mean pulmonary arterial pressure by a minimal\ud 10% post PADN) was achieved in 94% of all patients, with a mean absolute reduction in systolic pulmonary arterial\ud pressure and mean pulmonary arterial pressure within 24 hours of −10 mmHg and −7 mmHg, respectively. The average\ud increment in 6-minute walk distance after PADN was 94 m. Worse PAH-related events occurred in 10 patients (15%),\ud mostly driven by the worsening of PAH (12%). There were 8 (12%) all-cause deaths, with 6 (9%) PAH-related deaths.\ud Conclusions—PADN was safe and feasible for the treatment of PAH. The PADN procedure was associated with significant\ud improvements in hemodynamic function, exercise capacity, and cardiac function and with less frequent PAH-related\ud events and death at 1 year after PADN treatment. Further randomized studies are required to confirm the efficacy of\ud PADN for PAH.
- Published
- 2015
42. P4667Relationships between cigarette smoking, infarct size, and clinical outcomes in patients undergoing primary PCI For STEMI: a patient-level pooled analysis of 10 randomized trials
- Author
-
Redfors, B., primary, Furer, A., additional, Selker, H.P., additional, Thiele, H., additional, Patel, M.R., additional, Udelson, J.E., additional, Ohman, E.M., additional, Eitel, I., additional, Granger, C.B., additional, Maehara, A., additional, Kirtane, A.J., additional, Genereux, P., additional, Ben-Yehuda, O., additional, and Stone, G.W., additional
- Published
- 2017
- Full Text
- View/download PDF
43. 1285Progression of tricuspid regurgitation over time and outcome: new insights in the natural history
- Author
-
Prihadi, E.A., primary, Van Der Bijl, P., additional, Gursoy, E., additional, Abou, R., additional, Vollema, E.M., additional, Hahn, R.T., additional, Stone, G.W., additional, Leon, M.B., additional, Ajmone Marsan, N., additional, Delgado, V., additional, and Bax, J.J., additional
- Published
- 2017
- Full Text
- View/download PDF
44. 2000Determinants of progression from none and mild to moderate and severe native tricuspid regurgitation: results from a large-scale echocardiographic study
- Author
-
Prihadi, E.A., primary, Van Der Bijl, P., additional, Gursoy, E., additional, Abou, R., additional, Vollema, E.M., additional, Hahn, R.T., additional, Stone, G.W., additional, Leon, M.B., additional, Ajmone Marsan, N., additional, Delgado, V., additional, and Bax, J.J., additional
- Published
- 2017
- Full Text
- View/download PDF
45. Clinical Trial Design Principles and Endpoint Definitions for Transcatheter Mitral Valve Repair and Replacement: Part 1: Clinical Trial Design Principles A Consensus Document From the Mitral Valve Academic Research Consortium
- Author
-
Stone, G.W., Vahanian, A.S., Adams, D.H., Abraham, W.T., Borer, J.S., Bax, J.J., Schofer, J., Cutlip, D.E., Krucoff, M.W., Blackstone, E.H., Genereux, P., Mack, M.J., Siegel, R.J., Grayburn, P.A., Enriquez-Sarano, M., Lancellotti, P., Filippatos, G., Kappetein, A.P., and MVARC
- Subjects
mitral valve ,valve surgery (or cardiac surgery) ,heart failure ,mitral regurgitation ,valve intervention - Published
- 2015
46. Projectile penetration into representative targets
- Author
-
Stone, G.W., primary
- Published
- 1994
- Full Text
- View/download PDF
47. Reproducibility of endothelial shear stress and low density lipoprotein transport modeling in computed tomography angiographic imaging data
- Author
-
Sakellarios, A., primary, Bourantas, C.V., additional, Papadopoulou, S.L., additional, de Vries, T., additional, Kitslaar, P.H., additional, Girasis, C., additional, Naka, K.K., additional, Veldhof, S., additional, Stone, G.W., additional, Reiber, J.H.C., additional, Michalis, L.K., additional, Serruys, P.W., additional, de Feyter, P.J., additional, Garcia Garcia, H.M., additional, and Fotiadis, D.I., additional
- Published
- 2016
- Full Text
- View/download PDF
48. Paclitaxel-eluting versus bare metal stents in primary PCI: a pooled patient-level meta-analysis of randomized trials
- Author
-
Luca, G. De, Dirksen, M.T., Kelbaek, H., Thuesen, L., Vink, M.A., Kaiser, C., Chechi, T., Spaziani, G., Lorenzo, E. Di, Suryapranata, H., Stone, G.W., Luca, G. De, Dirksen, M.T., Kelbaek, H., Thuesen, L., Vink, M.A., Kaiser, C., Chechi, T., Spaziani, G., Lorenzo, E. Di, Suryapranata, H., and Stone, G.W.
- Abstract
Contains fulltext : 153576.pdf (publisher's version ) (Closed access), Concerns have emerged regarding a higher risk of stent thrombosis after drug-eluting stent (DES) implantation, especially in the setting of ST-segment elevation myocardial infarction (STEMI). Therefore, we performed a meta-analysis based on individual patient data to evaluate long-term safety and effectiveness of paclitaxel-eluting stent (PES) as compared to bare metal stents (BMS) in patients undergoing primary percutaneous coronary intervention (PCI) for STEMI. We examined all completed randomized trials on PES for STEMI. Individual patient data were obtained from six trials. We performed survival analyses with the use of Cox-regression analysis stratified according to trial. Kaplan-Meier survival curves are presented with event rates reported as estimated probabilities. A subsequent landmark analysis was performed for patients who were event-free at 1-year follow-up in order to define outcome in terms of early (=1 year) and late (>1 year) events. A total of six trials were finally included in the meta-analysis with 4435 patients, 2875 (64.8 %) assigned to PES and 1560 (35.2 %) to BMS. No significant differences in baseline characteristics were observed between the two groups. However, a significantly higher percentage of patients in the DES group were on dual antiplatelet therapy during 3-year follow-up, as compared to BMS. At long-term follow-up (1,095 [1,090-1,155] days), no significant difference between PES and BMS was observed in mortality (9.2 vs 11.9 %, respectively, HR [95 % CI] = 0.84 [0.67, 1.06], p = 0.15, pheterogeneity = 0.59), reinfarction (8.8 vs 7 %, respectively; HR [95 % CI] = 1.10 [0.84, 1.44], p = 0.51, pheterogeneity = 0.32), stent thrombosis (6.7 vs 4.0 % respectively, HR [95 % CI] = 1.13 [0.82, 1.55], p = 0.45, pheterogeneity = 0.99) and TVR (11.9 vs 20.0 %; HR [95 % CI] = 0.64 [0.54, 0.77], p < 0.0001, pheterogeneity = 0.25). Landmark analysis showed that PES was associated with a significantly higher rate of very late reinfarction (>1 y
- Published
- 2015
49. Two-year safety and effectiveness of the platinum chromium everolimus-eluting stent for the treatment of small vessels and longer lesions.
- Author
-
Dens J., Teirstein P.S., Meredith I.T., Feldman R.L., Rabinowitz A.C., Cannon L.A., Lee T.C., Dubois C.L., Stone G.W., Dawkins K.D., Allocco D.J., Saito S., Pompili V.J., Mooney M.R., Dens J., Teirstein P.S., Meredith I.T., Feldman R.L., Rabinowitz A.C., Cannon L.A., Lee T.C., Dubois C.L., Stone G.W., Dawkins K.D., Allocco D.J., Saito S., Pompili V.J., and Mooney M.R.
- Abstract
Objectives: To report 1- and 2-year clinical outcomes of patients receiving platinum chromium everolimus-eluting stents (PtCr-EES) in the prospective, single-arm PLATINUM small vessel (SV) and long lesion (LL) studies. Background(s): Small vessel diameter and long lesion length are independently associated with increased risk of adverse cardiac events after drug-eluting stent implantation. Method(s): The PLATINUM SV study enrolled 94 patients with coronary artery lesions in vessels <=2.25 mm to <2.50 mm in diameter and & <=28 mm in length. The PLATINUM LL study enrolled 102 patients with lesions >24 to & <=34 mm long in vessels <=2.50 to & <=4.25 mm in diameter. The primary endpoint for both studies was target lesion failure (TLF) at 1 year compared to a prespecified performance goal based on outcomes with the TAXUS Express paclitaxel-eluting stent in small vessels and long lesions. Result(s): One-year TLF rates with the PtCr-EES were significantly (P < 0.001) lower than the predetermined performance goals: 2.4% versus 21.1% in the SV cohort and 3.2% versus 19.4% in the LL cohort. Cumulative rates of TLF to 2 years were 4.7% in the SV cohort and 8.8% in the LL cohort. No myocardial infarction or ARC definite/probable stent thromboses occurred in either cohort through 2-year follow-up. Conclusion(s): The clinical efficacy and safety outcomes observed in these small vessel and long lesion cohorts support the use of the PtCr-EES in the treatment of small diameter vessels and long lesions.Copyright © 2014 Wiley Periodicals Inc.
- Published
- 2015
50. Long-term forecasting and comparison of mortality in the Evaluation of the Xience Everolimus Eluting Stent vs. Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL) trial: Prospective validation of the SYNTAX Score II
- Author
-
Campos, C.A.M. (Carlos), Klaveren, D. (David) van, Farooq, V. (Vasim), Simonton, C. (Charles), Kappetein, A.P. (Arie Pieter), Sabik, J.F. (Joseph), Steyerberg, E.W. (Ewout), Stone, G.W. (Gregg), Serruys, P.W.J.C. (Patrick), Campos, C.A.M. (Carlos), Klaveren, D. (David) van, Farooq, V. (Vasim), Simonton, C. (Charles), Kappetein, A.P. (Arie Pieter), Sabik, J.F. (Joseph), Steyerberg, E.W. (Ewout), Stone, G.W. (Gregg), and Serruys, P.W.J.C. (Patrick)
- Abstract
Aims To prospectively validate the SYNTAX Score II and forecast the outcomes of the randomized Evaluation of the Xience Everolimus-Eluting Stent Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL) Trial. Methods and results Evaluation of the Xience Everolimus Eluting Stent vs. Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization is a prospective, randomized multicenter trial desig
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.